

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Joseph G. Masterson et al.Application No./Patent No.: 5,540,938 Filed/Issue Date: July 30, 1996Entitled: Formulations And Their Use In The Treatment Of Neurological Diseases

Alkermes Pharma Ireland Limited

(Name of Assignee)

, a corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: the inventors To: Elan Corporation, plc

The document was recorded in the United States Patent and Trademark Office at

Reel 005690, Frame 0060, or for which a copy thereof is attached.

2. From: Elan Corporation, plc To: Elan Pharma International Limited

The document was recorded in the United States Patent and Trademark Office at

Reel 021266, Frame 0957, or for which a copy thereof is attached.

3. From: Elan Pharma International Limited To: EDT Pharma Holdings Limited

The document was recorded in the United States Patent and Trademark Office at

Reel 027528, Frame 0872, or for which a copy thereof is attached.

- ☒ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Richie Paul

Signature

23 February, 2012

Date

Richie Paul

Printed or Typed Name

+ 353 90 649 5000

Telephone Number

Director, Alkermes Pharma Ireland Limited

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Supplemental Sheet Accompanying Statement Under 37 CFR 3.73(b)

Patent No. 5,540,938

Issued: July 30, 1996

Entitled: Formulations And Their Use In The Treatment Of Neurological Diseases

4. From: EDT Pharma Holdings Limited To: Alkermes Pharma Ireland Limited

The document was recorded in the United States Patent and Trademark Office at

Reel: 027528, Frame: 0921.